FDA files motion to delay Endo litigation, again

Endo International said Thursday it will not oppose a request by the Food and Drug Administration for a further stay through March 15 of the company's ongoing litigation against the federal agency.   The litigation challenges the FDA's process for allowing the bulk compounding of certain drugs, including vasopressin, that have not satisfied the legal requirements of the Drug Quality and Security Act amendments to the Federal Food, Drug, and Cosmetic Act.  One of Endo's subsidiaries, Par St erile…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news